What is Twist Bioscience?
Twist Bioscience operates at the intersection of biotechnology and advanced manufacturing. By leveraging a proprietary silicon-based platform, the company enables the large-scale, high-precision synthesis of DNA, which serves as a foundational element for innovation in medicine, agriculture, and industrial biotechnology. Its market position is defined by its ability to deliver high-quality genetic material at unprecedented speed and scale, effectively removing bottlenecks in genetic research and therapeutic discovery. As a key player in the synthetic biology ecosystem, Twist Bioscience provides the essential building blocks that empower researchers to accelerate their development pipelines and achieve sustainable scientific breakthroughs.
How much funding has Twist Bioscience raised?
Twist Bioscience has raised a total of $728.7M across 14 funding rounds:
Multiple Rounds
$50.2M
Series C
$37M
Series D
$61M
Debt
$20M
Series E
$60M
Share Placement
$50M
Stock Offering
$69M
Stock Offering
$84.1M
Multiple Rounds
$297.4M
Series A (2014): $9.1M with participation from Undisclosed
Grant (2014): $5.1M led by DARPA
Series B (2014): $26M supported by Yuri Milner, ARCH Venture Partners, Paladin Capital Group, and Tao Invest
Debt (2014): $10M featuring Silicon Valley Bank
Series C (2015): $37M backed by Yuri Milner, Foresite Capital Management, ARCH Venture Partners, Paladin Capital Group, Illumina Inc., Tao Invest, and Fidelity Management & Research Company
Series D (2016): $61M with participation from Illumina Inc., Boris Nikolic, Yuri Milner, Tao Invest, Foresite Capital Management, ARCH Venture Partners, ARCH Overage Fund, Merieux Development, Cormorant Asset Management, Paladin Capital Group, Fidelity Management & Research Company, and WuXi Healthcare Ventures
Debt (2016): $20M led by Silicon Valley Bank
Series E (2017): $60M supported by 3W Partners Capital, KANGMEI Group, Biomatics Capital, Ditch Plains Capital Management, NFT Investment Limited, Bay City Capital, FIS Global, and Reinet Fund
Share Placement (2018): $50M featuring Undisclosed
Stock Issuance/Offering (2018): $69M backed by Undisclosed
Stock Issuance/Offering (2019): $84.1M with participation from Undisclosed
Stock Issuance/Offering (2020): $50M led by Undisclosed
Stock Issuance/Offering (2020): $140M supported by Undisclosed
Stock Issuance/Offering (2020): $107.4M featuring Undisclosed
Key Investors in Twist Bioscience
ARCH Venture Partners
ARCH Venture Partners is a leading early-stage venture capital firm that creates and invests in life sciences and advanced technology companies, often cofounding startups with scientists and entrepreneurs to commercialize innovations from universities, corporate R&D groups, and national laboratories.
Paladin Capital Group
Paladin Capital Group operates as a global multi-stage investment firm specializing in venture capital and growth financing across diverse sectors, leveraging deep sector expertise to accelerate growth trajectories.
Foresite Capital Management
Foresite Capital is a multi-stage investment firm focused on transforming healthcare and life sciences by investing in companies that utilize biology and big data to address significant unmet needs.
What's next for Twist Bioscience?
Looking ahead, the infusion of capital from recent financing rounds positions Twist Bioscience to further scale its operational capacity and expand its footprint in the global life sciences market. The company is expected to prioritize the enhancement of its silicon-based synthesis technology, aiming to drive down costs while increasing throughput for complex genetic applications. Strategic focus will likely remain on deepening partnerships within the pharmaceutical and biotech industries, where the demand for reliable, high-fidelity DNA remains a critical driver of drug development success. By maintaining its commitment to innovation and operational excellence, Twist Bioscience is well-equipped to capitalize on the growing convergence of genomics and digital data, ensuring its continued relevance in the rapidly evolving landscape of modern biotechnology.
See full Twist Bioscience company page
